Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence - Redeye

Redeye provides an update following Corline’s Q4 2025 report. Quarterly sales came in below our expectations, and we are still awaiting a clearer ramp-up linked to Kardium’s launch of the Globe system. Following the report, we have made some downward adjustments to our estimates, primarily FX-related but also reflecting a more cautious approach to near-term projections, resulting in an updated fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1151489/corline-biomedical-q4-review-case-intact-but-sales-ramp-up-needed-to-restore-market-confidence?utm_source=finwire&utm_medium=RSS